In the United States, the Multidisciplinary Association for Psychedelic Studies' (MAPS) investigation into MDMA-assisted psychotherapy for PTSD is currently on a fast track with the FDA, and physician prescribed psychedelic psychotherapy may be just a year or two away.
The results from the MDMA-assisted psychotherapy trials show clear improvements in symptoms of the disorder. After living with treatment-resistant depression for nearly two decades, 70% of those treated no longer meet criteria for PTSD.
The scientific study of psychedelic medicines like LSD, psilocybin mushrooms, MDMA, ayahuasca, DMT, mescaline/peyote, ketamine, and cannabis is very promising. Research investigating the transformational benefits of these compounds reveals that altered states of consciousness enhance creativity, and foster psychological, spiritual, and psychophysical healing.
In conclusion, the exciting progress in psychedelic research, especially with MAPS’ MDMA-assisted therapy for PTSD, suggests we may soon see these treatments become available. With 70% of participants showing significant improvement and the FDA’s interest, we’re on the verge of a new chapter in mental health care.
As we embrace these developments, there’s renewed hope for those struggling with mental health issues, paving the way for innovative and compassionate treatment options in the near future.
Comments